Investigational drug · Phase 2
Olaptesed pegol
Also called: NOX-A12
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Pancreatic Cancer, Glioblastoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Olaptesed pegol"
First trial start
2019
Sep 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olaptesed pegol", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Pancreatic Cancer
- Glioblastoma
Approved drugs for the same conditions: Pancreatic cancer · Brain tumors (glioma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Olaptesed pegol" as an intervention, largest first.
- Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated PatientsPivotal-lookingActive, not recruiting
TME Pharma AGIndustry
NCT04121455 · 117 participants (planned) · Start Sep 12, 2019 · Primary completion Dec 2028
Drug: Olaptesed pegol; Bevacizumab and 2 more · For: Glioblastoma
Sites: Bonn, Germany; Essen, Germany; Leipzig, Germany · 6 sites in all
- Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic CancerNot yet recruiting
TME Pharma AGIndustry
NCT04901741 · 60 participants (planned) · Start Jan 2026 · Primary completion Mar 2028
Drug: Olaptesed pegol; Pembrolizumab · For: Metastatic Pancreatic Cancer
- NOX-A12 First-in-human (FIH) StudyCompleted
TME Pharma AGIndustry
NCT00976378 · 48 participants · Start Oct 2009 · Primary completion May 2010
Drug: NOX-A12; NOX-A12 · For: Autologous Stem Cell Transplantation
Sites: Hamburg, Germany
TME Pharma AGIndustry
NCT01486797 · 28 participants · Start Mar 2012 · Primary completion Nov 2014
Drug: NOX-A12 · For: Chronic Lymphocytic Leukemia
Sites: Innsbruck, Austria; Salzburg, Austria; Steyr, Austria · 17 sites in all
- Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic CancerCompleted
TME Pharma AGIndustry
NCT03168139 · 20 participants · Start Apr 18, 2017 · Primary completion Mar 25, 2020
Drug: Olaptesed pegol - Monotherapy; Olaptesed pegol + Pembrolizumab - Combination Therapy · For: Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer
Sites: Heidelberg, Germany
TME Pharma AGIndustry
NCT01194934 · 12 participants · Start Aug 2010 · Primary completion Jan 2011
Drug: NOX-A12; NOX-A12 and 2 more · For: Hematopoietic Stem Cell Transplantation
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Aptamers in cancer research: Focus on leukemia.
Lin S, Liu T · Chin Med J (Engl) 2026
- Mapping Aptamer Prototypes to the Unmet Gaps of Glioblastoma Care: From Circulating Cells to the Resection Cavity.
Zamay GS, Luzan NA, Koshmanova AA, et al. · Cancers (Basel) 2026
- SDF-1 Inhibition Attenuates VEGF-Driven Retinal Leukostasis and Neovascularization in Ischemic Retinopathy.
Ye Y, Long J, Hu P, et al. · J Ocul Pharmacol Ther 2026
- Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner.
Makranz C, Huguely C, Zhang M, et al. · Neurooncol Adv 2026
- Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?
Tran TT, Tran VL, Fishel ML, et al. · Biomed Pharmacother 2026
- L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.
Giordano FA, Layer JP, Turiello R, et al. · Nat Commun 2026
Also in development for Metastatic Pancreatic Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- SurufatinibPhase 31 trial
Hutchmed · Metastatic Pancreatic Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- HY-0102Phase 21 trial
Shanghai YingLi Pharmaceutical Co. Ltd. · Metastatic Pancreatic Cancer
- YL-13027Phase 21 trial
Shanghai YingLi Pharmaceutical Co. Ltd. · Metastatic Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.